BIOCAD sell "Rituximab"

This rituximab biosimilar is a chimeric monoclonal antibody that specifically binds the transmembrane antigen CD20, indicated for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA). It has treated over 60,000 patients, with more than 700,000 vials sold, and is marketed in 19 countries.